Neu5Gc-containing antigens for cancer prognosis and monitoring Sequential serum Neu5Gc levels measured over time from 15 breast cancer patients at high-risk for recurrence (6 patients in remission and 9 patients with recurrence) detected using a SubB2M-SPR-based assay showed a decreasing trend following the first line of treatment in those patients in remission [30] ( Table 1 ).
1
—
—